Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J DeAngelo

Showing results (111-120 of 320) with videos related to

Pageof 32
Sort By:
Blood Advances|April 25, 2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)Jeffrey E Lancet, Anna B Moseley, Steven E Coutre, et al.
Blood|March 9, 2007
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo, Daohai Yu, Jeffrey L Johnson, et al.
American Journal of Hematology|April 10, 2021
Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following inductionJ Erika Haydu, Yael Flamand, Rahul S Vedula, et al.
Blood|May 10, 2003
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationMartha Wadleigh, Paul G Richardson, David Zahrieh, et al.
Cancer|August 8, 2013
Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklistOreofe O Odejide, Angel M Cronin, Daniel J DeAngelo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 4, 2020
Detection of the KIT<sup>D816V</sup> mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosisJeffrey W Craig, Robert P Hasserjian, Annette S Kim, et al.
British Journal of Haematology|August 18, 2020
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicinRyan D Cassaday, David I Marks, Daniel J DeAngelo, et al.
Leukemia & Lymphoma|May 8, 2020
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study databaseElias Jabbour, Matthias Stelljes, Anjali S Advani, et al.
Leukemia & Lymphoma|February 15, 2021
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndromeGail J Roboz, Pinkal Desai, Sangmin Lee, et al.
Cancer|January 31, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATEElias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, et al.
Pageof 32

Showing results (111-120 of 320) with videos related to

Sort By:
Pageof 32
Blood Advances|April 25, 2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)Jeffrey E Lancet, Anna B Moseley, Steven E Coutre, et al.
Blood|March 9, 2007
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Daniel J DeAngelo, Daohai Yu, Jeffrey L Johnson, et al.
American Journal of Hematology|April 10, 2021
Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following inductionJ Erika Haydu, Yael Flamand, Rahul S Vedula, et al.
Blood|May 10, 2003
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationMartha Wadleigh, Paul G Richardson, David Zahrieh, et al.
Cancer|August 8, 2013
Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklistOreofe O Odejide, Angel M Cronin, Daniel J DeAngelo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 4, 2020
Detection of the KIT<sup>D816V</sup> mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosisJeffrey W Craig, Robert P Hasserjian, Annette S Kim, et al.
British Journal of Haematology|August 18, 2020
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicinRyan D Cassaday, David I Marks, Daniel J DeAngelo, et al.
Leukemia & Lymphoma|May 8, 2020
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study databaseElias Jabbour, Matthias Stelljes, Anjali S Advani, et al.
Leukemia & Lymphoma|February 15, 2021
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndromeGail J Roboz, Pinkal Desai, Sangmin Lee, et al.
Cancer|January 31, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATEElias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, et al.
Pageof 32